MUNICH and FRANKFURT, Germany, September 18, 2018 /PRNewswire/ — Pioneering project will enable start-ups to accelerate time to market for innovative health-related products and services aescuvest and EIT Health announce … Continue reading “aescuvest and EIT Health Launch First Pan-European Equity Crowdfunding Platform for Healthcare”
CALGARY, Alberta and SAN DIEGO, Sept. 17, 2018 (GLOBE NEWSWIRE) — Oncolytics Biotech® Inc. (TSX: ONC) (NASDAQ: ONCY), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors … Continue reading “Oncolytics Biotech® Announces Investigator Sponsored Multiple Myeloma Study Combining REOLYSIN® and Nivolumab (Opdivo®) with Standard of Care”
LONDON, 12 September 2018: Arix Bioscience plc (“Arix”) (LSE: ARIX), a global healthcare and life science company supporting medical innovation, today announced that industry veteran Arthur Pappas has been appointed … Continue reading “ARIX Bioscience Plc Announces Board Changes, Appointment of Arthur Pappas to the Board of Directors, David U’Prichard to retire from Board”
CALGARY, Alberta and SAN DIEGO, Sept. 06, 2018 (GLOBE NEWSWIRE) — Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors … Continue reading “Oncolytics Biotech® Announces a Master Clinical Supply Agreement of an Anti-PD-L1 Checkpoint Inhibitor for use in the Company’s Clinical Program”
Forendo Pharma, a clinical stage drug development company focusing on novel treatments in women’s health, today announces that it has raised an additional €4 million of funding from Vesalius Biocapital … Continue reading “Vesalius Biocapital III Partners joins Forendo Pharma Investor Syndicate”
Probiodrug AG (Euronext Amsterdam: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), today announced that Dr. Michael Schaeffer has been appointed to the … Continue reading “Probiodrug Appoints Dr. Michael Schaeffer as Executive Vice President of Business and Strategy”
Azeria Therapeutics Limited, a newly formed drug discovery company, today announced that it has successfully raised £4 million in Series A fundraising from the £70 million CRT Pioneer Fund, managed … Continue reading “Azeria Therapeutics, the world’s first pioneer factor drug discovery company, announces Series A investment from Sixth Element Capital”
Amsterdam, The Netherlands, August 30, 2018 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announces that Robbert van Heekeren is … Continue reading “Kiadis Pharma announces resignation of Robbert van Heekeren and appoints Scott A. Holmes as new Chief Financial Officer”
Novo Nordisk gains full rights to Ziylo’s early-stage glucose binding molecules in a staged acquisition with a potential deal value that could exceed 800 million US dollars The acquisition supports … Continue reading “Novo Nordisk acquires Ziylo Ltd to accelerate its development of glucose responsive insulins”
Ziylo’s technology platform could accelerate the development of a groundbreaking treatment for diabetes patients A new company, Carbometrics, has been set up to develop novel diagnostics and glucose monitoring BRISTOL, … Continue reading “Ziylo acquired by Novo Nordisk in deal that could exceed US$800m”
Arix interest increased to £15.3 million ($19.7 million1), becoming largest shareholder in Artios. Supporting proven management team in accelerating development of next generation DNA Damage Response (DDR) pipeline Arix Bioscience … Continue reading “Arix Bioscience Plc – Artios completes £65m Series B investment round”
Financing Round Led by New Investors Andera Partners and LSP Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company developing innovative treatments for cancer, today announced the completion … Continue reading “Artios Pharma Announces $84 million (£65 million) Series B Financing”
Arix Bioscience leads A$24 million (£13.4 million) financing for Pharmaxis Funding to accelerate the development of Pharmaxis’ fibrosis and anti-inflammatory programmes, as the company advances numerous candidates from its Amine … Continue reading “Arix Bioscience announces first VIPE investment”
The oncolytic virus renaissance: improving the efficacy of current immunotherapies Oncolytics Biotech Inc. featured in the pharmphorum’s Deep Dive on Oncology Pharma companies are turning to oncolytic viruses to increase … Continue reading “Oncolytics Biotech: The oncolytic virus renaissance: improving the efficacy of current immunotherapies”
Silence Therapeutics plc, AIM:SLN (“Silence” or “the Company”) a leader in the discovery, delivery and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, … Continue reading “Silence Therapeutics Technology Licensee Quark Pharmaceuticals announces First Patient Dosed in Phase 3 Clinical Trial for Acute Kidney Injury”
Turku, Finland, July 4 2018: Forendo Pharma, a drug development company focusing on novel oral treatments for endometriosis patients, today announces it has received clinical trial authorisation (CTA) from the … Continue reading “Forendo Pharma initiates phase I study for potential new, targeted treatment for endometriosis”
The majority of the questions in this LSX survey are multiple choice, therefore it should take you no longer than 10 minutes to complete. LSX C-Suite Survey Please note that … Continue reading “The LSX C-Suite Challenges in Life Sciences Survey 2018”
Hamburg, Germany, 18 June 2018: Evotec AG today announced having signed a transaction agreement with Sanofi to integrate Sanofi’s infectious disease unit into its organisation. Pursuant to this agreement, Evotec … Continue reading “Evotec and Sanofi sign definitive agreement to combat infectious diseases”
HASSELT, Belgium and CHEPSTOW, Wales, April 16, 2018 /PRNewswire/ — Phase I data show early efficacy in the majority of patients and a very favourable safety profile Apitope, a clinical stage biotech company developing potential first-in-class antigen-specific … Continue reading “Apitope Announces Positive Results with Novel Treatment for Graves’ Disease”
For more information about Optimum Strategic Communications, please get in touch
We'd love to hear from you...
GET IN TOUCH
© Copyright 2018 Optimum Strategic Communications All rights reserved.
9 Devonshire Square
London
EC2M 4YF
Tel: +44 (0)203 714 1788
Email: contact@optimumcomms.com